

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



A14

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>5</sup> :  C12N 15/10, 15/12</p>	<p>A1</p>	<p>(11) International Publication Number: WO 93/10230  (43) International Publication Date: 27 May 1993 (27.05.93)</p>
<p>(21) International Application Number: PCT/US92/10087 (22) International Filing Date: 18 November 1992 (18.11.92)  (30) Priority data: 796,066 20 November 1991 (20.11.91) US  (71) Applicant: TRUSTEES OF DARTMOUTH COLLEGE [US/US], Hanover, NH 03755 (US). (72) Inventor: SMITH, Kendall, A. ; 11 Pleasant Street, Han- over, NH 03755 (US). (74) Agents: DeCONTI, Giulio, A., Jr. et al.; Lohive &amp; Cock- field, 60 State Street, Boston, MA 02109 (US).</p>		<p>(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE).  Published <i>With international search report.</i></p>
<p>(54) Title: LIGAND-STIMULATED GENE EXPRESSION</p> <p>(57) Abstract</p> <p>Disclosed is a method of producing a complementary DNA (cDNA) library enriched in ligand-inducible genes of a cell. The method includes activating a cellular ligand receptor for a predetermined period of time in the presence of labelled RNA precursors and a substance which enhances the level of RNA in said cell. The RNA precursors are incorporated into the RNA synthesized by said cell in response to receptor activation. The labelled RNA is separated from unlabelled RNA and used to prepare cDNA. The cDNA is cloned into host cells to provide a first cDNA library of cDNA-containing clones, which is then screen for clones containing ligand-induced genes. Clones containing ligand-inducible genes are selected to produce a second cDNA library enriched in ligand-inducible genes.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

-1-

## LIGAND-STIMULATED GENE EXPRESSION

Background of the Invention

Mammalian cell growth, differentiation, and migration are directed by hormones and specific protein ligands, often termed cytokines. In particular, cells comprising the neuro-endocrine, hematopoietic and the immune/inflammatory systems are known to be governed by cytokines. Cytokines, like other ligands, interact with cells by means of specific receptors, usually expressed on the cell surface.

A fundamental problem confronting biomedical scientists is to discern how signals are transduced through ligand receptors and how these signals determine the response of the cell. Many ligands influence their target cells by stimulating the expression of specific genes. However, the genes signaled by most cytokines remain largely unknown owing to the complexity of cellular biochemistry. Moreover, the gene products that are vital for performing different cellular processes are often only expressed transiently, and/or in very low concentrations so that they are difficult to detect, isolate and characterize.

Interleukin-2 (IL-2) is a cytokine that is critical for the immune system: it directs the proliferation and differentiation of T lymphocytes (T-cells), B lymphocytes (B-cells), and natural killer

(NK) cells. Just how IL-2 signals these cellular events in the various types of target cells remains unknown. A few genes have been identified that are expressed as the result of IL-2 stimulation of T  
05 cells. These include the cellular proto-oncogenes c-fos, c-myb, c-myc, pim-1, and c-raf-1. However, exactly how many and what other genes are expressed as a result of IL-2/IL-2 receptor interaction remains unknown.

10 Since the discovery of DNA cloning, methods have become available to isolate specific genes expressed by cells. However, it has been difficult to devise new methods to isolate and clone all or most of the genes expressed by a cell activated by a given ligand,  
15 a task that must be done before one can understand how the ligand directs the cell to perform specific functions. In addition, methods of identifying a particular gene or genes stimulated early on after ligand receptor activation have not been easily  
20 forthcoming as the number of genes stimulated by receptor activation from which a particular gene must be selected is usually quite large.

Therefore, what is needed are methods to select and enrich only for those genes stimulated by a given  
25 ligand. Ideally, these methods should detect those genes expressed in low concentrations, as well as those expressed at high concentrations.

Summary of the Invention

This invention pertains to complementary deoxyribonucleic acid (cDNA) libraries enriched in clones containing genes induced by ligand stimulation of a cell having a corresponding receptor for the ligand, and to methods of producing the same. This invention also relates to the genes which are expressed immediately or early on as a consequence of such a ligand-receptor interaction, and to methods of identifying these genes.

In the method of producing a cDNA library enriched in ligand-inducible genes, a cellular ligand receptor on a cell is activated with a ligand, for a predetermined period of time, to induce expression of those genes expressed as a result of ligand-receptor binding. Useful ligands include any of those which can activate a specific cellular receptor. These include natural or synthetic ligands for the receptor. Ligands include cytokines such as the interleukins, cellular growth factors, colony stimulating factors, hormones, peptides, antibodies, and receptor-binding fragments thereof.

The cells are activated with the ligand in the presence of labelled RNA precursors. These precursors are incorporated into RNA synthesized by the cell in response to receptor activation. Labelled precursors are used in order to distinguish newly transcribed RNA from unlabelled, preexisting RNA. Preferred labelled RNA precursors include 6-thioguanine, 4-thiouridine, and tritiated uridine.

Activation is also carried out in the presence of a substance which enhances the level of RNA in a cell. Preferred substances include the protein synthesis inhibitors, cycloheximide and puromycin.

05 Other useful substances include cyclic 3',5'-adenosine monophosphate (cAMP), analogs of cAMP such as dibutyryl cAMP, and other molecules which increase the intracellular level of cAMP. The labelled RNA is then separated from the unlabelled RNA and used to prepare

10 cDNA.

The cDNA is cloned into host cells to provide a first cDNA library of cDNA-containing clones. This library is screened for clones containing ligand-inducible genes, and these clones are selected

15 to produce a second cDNA library enriched in ligand-inducible genes.

In one embodiment of the invention, the screening step includes probing the first cDNA library with a DNA probe constructed from total cellular RNA or mRNA

20 derived from (1) a ligand-induced cell and from (2) an uninduced cell. The library is probed under conditions such that the probe hybridizes specifically with complementary cDNA sequence in the first library. The selecting step includes selecting those

25 clones containing sequences that hybridize only with probes constructed from ligand-induced mRNA or total RNA.

Alternatively, the screening step involves probing the first library with an excess of RNA

30 obtained from an uninduced cell under conditions such that the RNA hybridizes specifically with complementary cDNA sequences in the library. The clones containing cDNA which hybridizes to both

ligand-induced and uninduced RNA are then removed, leaving clones containing cDNA common to only ligand-induced cells.

By following the method of the invention, a second cDNA library of clones enriched in genes induced by ligand binding have been prepared. Some of these clones contain the DNA sequences set forth in the Sequence Listing as SEQ ID NOS: 1-19.

#### Brief Description of the Figures

- 10 The foregoing and other objects of this invention, the various features thereof, as well as the invention itself, may be more fully understood from the following description, when read together with the accompanying drawings, in which:
- 15 FIGS. 1A-1H are photographic representations of Northern blots using RNA isolated from uninduced and induced (with CHX, IL-2, or IL-2 + CHX) T-cells and the following cloned cDNA probes: FIG. 1A, clone 1A8; FIG. 1B, clone 10A8; FIG. 1C, clone 10F9; FIG. 1D, clone 1F5; FIG. 1E, clone 10D6; FIG. 1F, clone 11B2; FIG. 1G, clone 10E6; FIG. 1H, clone 13E2;
- 20 FIGS. 2A-2H are photographic representations of Northern blots using RNA isolated from control and IL-2-induced (in the presence or absence of cAMP or NaBt) T-cells and the following cloned cDNA probes: FIG. 2A, clone 1A8, FIG. 2B, clone 10D6; FIG. 2C, clone 13E2; FIG. 2D, clone 1F5; FIG. 2E, clone 10A8; FIG. 2F, clone 10F9; FIG. 2G, clone 11B2; FIG. 2H, clone 11E6;

FIGS. 3A-3H are photographic representations of Northern blots using RNA isolated from T-cells whose T-cell antigen receptor had been untreated or treated (with CHX, antibody OKT3, or OKT3 + CHX) and the following cloned cDNA probes: FIG. 3A, clone 10A6; FIG. 3B, clone 1A8; FIG. 3C, clone 1F5; FIG. 3D, clone 10A8; FIG. 3E, clone 10F9; FIG. 3F, clone 11B2; FIG. 3G, clone 11E6; FIG. 3H, clone 13E2;

FIG. 4 is a histogram showing the level of DNA synthesis (as the incorporation of [<sup>3</sup>H]-thymidine in PBMN cells treated with CHX, OKT3 or OKT3 and CHX; and

FIG. 5A-5H are photographic representations of Northern blots showing the kinetics of IL-2-induced gene expression. RNA from unstimulated, IL-2-stimulated, or IL-2 + 10 µg/ml CHX-stimulated cells was probed with cDNA inserts of the following IL-2-induced clones: FIG. 5A, clone 1A8, FIG. 5B, clone 10D6; FIG. 5C, clone 1F5; FIG. 5D, clone 10A8; FIG. 5E, clone 10F9; FIG. 5F, clone 11B2; FIG. 5G, clone 11E6; FIG. 5H, clone 13E2.

#### Description of the Invention

By combining several different procedures, a cDNA library can be constructed which is enriched in clones containing genes whose expression is induced by activation of a cellular ligand-specific receptor. This enriched library can facilitate identification and characterization of ligand-activated genes that are triggered immediately and/or early on after receptor activation (e.g., 2 to 4 hours after the ligand binds to its receptor). Such genes may play a role in stimulating growth phase transitions and subsequent clonal expansion of a particular cell type.



The method of the invention can be used to create cDNA libraries of the genes induced by activation of a variety of different cellular receptors. The receptors can be cytoplasmic, nuclear, or cell-surface  
05 receptors, and include receptors for cytokines, hormones, factors, and peptides. For example, cytokines such as the interleukins (e.g., IL-1 and IL-2), cellular growth factors (e.g., platelet-derived growth factor (PDGF), epidermal growth factor (EGF),  
10 fibroblast growth factor (FGF), insulin-like growth factor (IGF)), colony stimulating factors (e.g., multiplication stimulating activity), and hormones (e.g., insulin, somatomedin C, and steroid hormones are useful as activators of certain cellular receptors.

15 The ligand used to activate the receptor can be the natural ligand recognized by the receptor or a synthetic analog. Alternatively, an antibody specific for the receptor and capable of activating the receptor may be used.

20 The receptor is activated by a ligand or other activation for a predetermined length of time and at a concentration necessary to activate the receptor. This activation is carried out in the presence of labelled RNA precursors which are incorporated into  
25 the RNA synthesized by the cell in response to receptor activation. Thus, the RNA transcribed is labelled so as to be distinguished from preexisting RNA which is not labelled.

Some labels (such as radiolabels) may be employed  
30 to monitor the newly synthesized RNA. Useful radiolabelled RNA precursors for such purposes include [<sup>3</sup>H]-uridine. Other labels may be used to separate newly transcribed RNA from unlabelled RNA. For

example, RNA synthesized from thiol-labelled RNA precursors specifically adheres to phenylmercury agarose (Woodford *et al.* (1988) *Anal. Biochem.* 178:166-172). RNA newly synthesized in response to  
05 receptor activation can be separated from preexisting RNA in the cell; all RNA molecules expressed prior to ligand-activation pass through the phenylmethyl mercury column, leaving only the newly synthesized, thiol- (SH-) labelled RNA attached to the agarose via  
10 a covalent bond between the mercury and sulfur. The thiol-labelled RNA molecules are then eluted from the column by reducing the Hg-S bond with an excess of 2-mercaptoethanol.

To augment the expression of immediate/early  
15 ligand-activated genes which may be difficult to identify because of the large number of downstream genes turned on at a later time, a substance that enhances the level of RNA is added to the culture medium during the ligand stimulation (see, e.g.,  
20 Cochran *et al.* (1983) *Cell* 33:939-947). Useful substances include those compounds that stabilize RNA and/or that block translation, thereby blocking feedback inhibition of these genes by a later gene product. Such activity may potentiate the magnitude  
25 of the RNA expressed as well as the duration of the life of the RNA. Examples of such useful substances include cyclohexamide (CHX), which inhibits protein synthesis at the level of RNA-ribosome complexing and may stabilize polysomal RNA, and puromycin, which  
30 inhibits translation by causing premature dissociation of the peptide-mRNA-ribosome complex.

cAMP is another useful substance which enhances the level of RNA. Increased levels of cAMP, or analogs or agents that elevate cAMP levels, such as forskolin, dibutyryl AMP, and isobutylmethyl xanthene, are known to inhibit cell growth, proliferation, and inositol phospholipid turnover. In addition, elevated levels of cAMP completely inhibit IL-2-stimulated T-cell proliferation (Johnson et al. (1988) Proc. Natl. Acad. Sci. (USA) 85:6072-6076).

10 The labelled RNA transcribed consequent to receptor activation in the presence of the substance which enhances RNA levels is then purified from the cytoplasm of the cells. Purification can be accomplished by extracting total cellular RNA from a  
15 cell homogenate or fraction thereof, isolating mRNA therefrom, for example, using a poly U or poly[dT] column, and then separating the labelled RNA from the unlabelled RNA. Separation can be accomplished, for example, using the phenylmethyl mercury agarose  
20 protocol described above. Of course, other known methods of separating the newly synthesized RNA from the preexisting may be used as well.

The cDNA libraries can be prepared from the separated labelled RNA by standard techniques. For  
25 example, the labelled RNA may be reversed transcribed into cDNA, using oligo[dT] primers. The cDNA is then ligated into appropriate vectors using established recombinant DNA techniques. A cDNA library is then constructed by methods well known in the art in  
30 prokaryotic or eucaryotic host cells that are capable of being transfected by the vectors.

Prokaryotic systems most commonly utilize E. coli as host, although other bacterial strains such as Bacillus, Pseudomonas, or other Gram-positive or Gram-negative prokaryotes can also be used. When such  
05 prokaryotic hosts are employed, operable control systems compatible with these hosts are ligated to the cDNA fragments and disposed on a suitable transfer vector which is capable of replication in the bacterial host cell. Backbone vectors capable of  
10 replication include phage vectors and plasmid vectors, as is known in the art. Common plasmid vectors include those derived from pBR322 and the pUC series. One such useful vector which is commercially available is the plasmid pBluescriptTIISK+ (Stratagene, La  
15 Jolla, CA). Charon lambda phage is a frequently employed phage vector. Control sequences obligatorily include promoter and ribosome binding site encoding sequences, and a variety of such controls are available in the art, such as the beta-lactamase  
20 (pencillinase) and lactose (lac) promoter systems (see, e.g., Chang et al. (1977) Nature 198:106), and the tryptophan (trp) promoter systems (Goeddel et al. (1980) Nucleic Acids Res. 8:4057. Composite promoters containing elements of both the trp and lac promoter  
25 systems are also available in the art.

Eucaryotic microbes, such as laboratory strains of Saccharomyces cerevisiae, or Baker's yeast, may also be used for expression. A number of yeast control systems and vectors are available, including  
30 those which are promoters for the synthesis of

glycolytic enzymes (see, e.g., Hess et al. (1968) Biochem. 17:4900). Yeast vectors employing the 2 micron origin of replication are suitable as transfer vectors (see, e.g., Broach (1982) Meth. Enzym. 101:307).

Tissue cultures of insect cell lines, or cell lines immortalized from mammalian or other higher organisms have also been used as recombinant hosts. Such cell lines include chinese hamster ovary (CHO), Vero, HeLa, and COS cells. In general, the COS cell system is used for transient expression, while CHO cells typically integrate transformed DNA into the chromosome. Suitable mammalian vectors are generally based on viral origins of replication and control sequences. Most commonly used are the simian virus 40 (SV40) promoters and replicons (see Fiers et al. (1978) Nature 273:113) and similar systems derived from Adenovirus 2, bovine papilloma virus, and avian sarcoma virus.

The ligand-activated genes are then screened in the library using any one of several different methods. One method involves differential hybridization with cDNA probes constructed from mRNA derived from ligand-activated cells and unactivated cells. Another method includes hybridization subtraction, whereby cDNA from ligand-activated cells is hybridized with an excess of mRNA from unactivated cells to remove RNA molecules common to both. Alternatively, cDNA probes can be made from the same pool of thiol-selected mRNA used to make the cDNA library, as these sequences are highly enriched for ligand-induced molecules. One can prepare cDNA probes from mRNA extracted from cells treated with drugs that

block the biologic response to the particular cytokine (e.g., rapamycin blocks the proliferative response of T cells to IL-2, and cyclosporinA and FK506 block the T-cell response to activation via the T-cell antigen  
05 receptor). Results from probing with the cDNA made from drug-inhibited cells can then be compared to results from probes made from cells not inhibited by these drugs.

The marked superinduction observed for a number  
10 of the genes using a substance, such as CHX, which enhances RNA levels is crucial in enabling their detection by differential hybridization, as it has been estimated that differential hybridization is only effective in the detection of relatively  
15 high-abundance RNAs expressed at a level of greater than 500 copies per cell. Therefore, the superinduction increases that level of expression of low-abundance RNAs above the threshold of detection by differential screening. In addition, the  
20 approximately 10-fold enrichment for newly synthesized RNA afforded by the thiol-labelling procedure further heightens the efficacy of the cloning procedure. Thus, the combination of superinduction and thiol-labelling of RNA significantly enhances the  
25 sensitivity of differential screening, and provides a cloning strategy which has the capacity to detect messages normally present in relatively low abundance (i.e., less than 100 copies/cell).

After the initial screening of the cDNA library, all clones isolated as tentatively positive must be corroborated as truly ligand-activated. This can be accomplished by isolating the cDNA insert from each  
05 cloned plasmid, and then employing this cDNA to probe RNA from ligand-activated cells by Northern blot analysis.

Then, to identify each gene, the cDNA may be subjected to sequence analysis. Searches of the  
10 GenBank (Los Alamos, NM) and EMBL (Heidleberg, Germany) data bases may be made of even partial sequences to identify known sequences such as pim-1, (SEQ ID NO:20), a previously characterized, IL-2 induced gene.

15 A number of methods can be used to characterize the novel ligand-enhanced genes and begin to determine their functional roles in, for example, signal transduction. DNA sequence analysis of the cDNA of the mRNA transcript can predict the coding region for  
20 the gene product and the amino acid sequence. From the amino acid sequence, the gene product can be placed into one of several categories of proteins, such as DNA-binding proteins, kinases, phosphatases, transmembrane proteins, or secreted products. These  
25 categories then will predict certain obvious functions and characteristics to be examined.

For example, the mechanism whereby IL-2 binding to its heterodimeric p55/p75 receptor on the cell surface activates specific gene expression is not well  
30 understood. The 75 kD component of the IL-2 receptor, which is responsible for signal transduction, does not exhibit sequence homologies indicative of previously characterized functional domains. However, the

involvement of protein phosphorylation in the IL-2 response has been indicated by the activation of IL-2R-associated kinases, including the tyrosine kinase p56<sup>lck</sup>, as well as the cytoplasmic serine/threonine kinase c-raf-1 in early IL-2-mediated transmembrane signalling. In addition, a number of proteins, including the IL-2R p75, are rapidly phosphorylated in response to IL-2. The hydrolysis of phosphatidylinositol glycan is also stimulated by IL-2, resulting in the formation of the putative second messengers myristylated diacylglycerol and inositol phosphate-glycan. Analysis of the regulatory elements governing expression of the immediate-early genes described in the present study will be useful in the further characterization of the secondary biochemical messengers activated by the IL-2 receptor.

Other methods helpful in determining the functional relevance of the IL-2-induced genes include examining T-cells for their expression in response to triggering of other receptors.

One such receptor is the T-cell antigen receptor. Seminal studies of the T-cell system have demonstrated that T-cell activation occurs as a two-step process. Quiescent cells are initially stimulated through engagement of the antigen receptor, which provides the cells with the capacity to produce and respond to IL-2. Subsequently, the interaction of IL-2 with its cell-surface receptor drives progression through the G<sub>1</sub> to the S phase of the cell cycle. Transmembrane signalling through both the T-cell antigen receptor has been shown to trigger the heightened expression of a number of genes, including



c-fos, c-myc and c-raf-1 (Reed *et al.* (1986) *Proc. Nat. Acad. Sci. (USA)* 83:3982-3986; Dautry *et al.* (1988) *J. Biol. Chem.* 263:17615-17620; and Zmuidzinas *et al.* (1991) *Mol. Cell. Biol.* 11:2794-2803). By  
05 comparison, in the case of the c-myc gene, the  
induction is unique to the IL-2 signalling pathway  
(Stern *et al.* (1986) *Science* 233:203-206). Therefore,  
to categorize the novel IL-2-induced genes with regard  
to their patterns of induction by these two receptor  
10 pathways, the sensitivity of the genes to T-cell  
receptor stimulation can be determined.

Additional methods that can be used to categorize  
the genes isolated include screening for expression by  
proliferating versus non-proliferating cells, for  
15 tissue-specific expression, and for expression in  
response to different cytokines and hormones. Genes  
that are expressed exclusively by proliferating cells  
are obvious candidates for functioning to promote cell  
growth. Other genes may be important for signaling  
20 differentiation and would be expected to be  
tissue-specific or activated only by a restricted  
family of similar ligands.

An additional means of elucidating the mechanisms  
of IL-2-mediated transmembrane signalling is provided  
25 by the varied effects of elevated cAMP on IL-2-induced  
gene expression. The diverse responses of the genes  
to cAMP suggest that the IL-2 signalling pathways  
responsible for their induction must bifurcate at a  
point prior to intersection with the cAMP regulated  
30 pathways. One potential mechanism of cAMP action may  
involve regulation of protein phosphorylation, as cAMP  
is an activator of protein kinase A, and elevations of  
intracellular cAMP inhibit IL-2-induced

phosphorylation events. In addition, as cAMP blocks IL-2-stimulated cell cycle progression at a point in early G<sub>1</sub>, cAMP sensitivity is a useful tool with which to dissect IL-2-mediated signal transduction pathways involved in cell cycle progression.

A likely function of the immediate/early gene products is the governing of subsequent DNA replication and cell division. Previously characterized IL-2 induced genes encode kinases (c-raf-1, pim-1) and DNA binding proteins (c-fos, c-myc, c-myb). Further sequence analysis of the novel genes will determine whether the proteins they encode contain conserved domains which would implicate similar functions. However, since IL-2 stimulates cellular differentiation as well as division, and has been shown to induce the expression of a number of genes which do not per se perform a direct role in cell cycle progression, a functional correlation between the expression of the novel genes and cell cycle transit should be demonstration.

Indirectly, cAMP sensitivity is suggestive of involvement in G<sub>1</sub> progression. The demonstration of induction of the genes by other growth factors, as well as heightened expression in transformed cell lines would further support this notion. A more direct approach, utilizing antisense oligonucleotides, will make it possible to determine whether specific blockage of expression of any of these genes is sufficient to prevent cell cycle progression.

Similarly, it will be possible to determine whether the immediate early gene products exert cell cycle control through the induction of expression of late genes, as has been demonstrated for regulation of the

PCNA/cyclin, DNA polymerase  $\alpha$  and cdc2 genes by the c-myb and c-myc gene products. Interestingly, the IL-2-induced expression of the PCNA/cyclin and DNA topoisomerase II gene in late G<sub>1</sub> is specifically  
05 inhibited by cAMP, so that cAMP sensitivity of immediate early gene expression may provide a useful indicator of which genes play a role in regulating late gene expression. If, like the previously characterized cell cycle regulatory cdc2/CDC28 and  
10 cyclin genes, the novel IL-2 induced genes are highly conserved, then it may ultimately be possible to isolate yeast homologs of the clones and perform deletional analyses to further define the functions of the gene products.

15 Ultimately, the definitive assignment of a given gene product to a particular function within a cell depends upon a series of different approaches, including determining intracellular location, and determining the consequences of blocking the  
20 expression of the gene either by mRNA antisense methods or by homologous recombination methods. All of the methods necessary for these studies exist as prior art and therefore, given the identification of a given gene as activated by a ligand such as the  
25 cytokine IL-2 is possible to characterize each gene product.

The invention is illustrated further by the following exemplification which is not meant to limit the scope of the invention, since alternative methods  
30 may be used to obtain similar results.

EXAMPLES

## 1. Cell Culture

Human peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll/Hypaque discontinuous centrifugation, and cultured at  $10^6$  cells/ml in complete medium comprised of RPMI 1640 (GIBCO Laboratories, Grand Island, NY) supplemented with 10% heat-inactivated (56°C, 30 min) calf serum (Sterile Systems, Inc., Logan, UT), 50 mg/ml L-glutamine, and 50 units/ml penicillin. T-cells were activated by stimulation of the CD3 component of the T-cell receptor complex with an anti-CD3 reactive monoclonal antibody (OKT3, 1:10,000 dilution, Ortho Pharmaceuticals, Raritan, NJ) in the presence of absence of 10 µg/ml CHX, and DNA synthesis was monitored at 48-52 hr by adding 0.5 µCi [ $^3$ H]-thymidine to 200 µl aliquots of cell cultures in 96-well microtiter plates. Cultures were harvested onto glass fiber filters, radioactivity was counted by liquid scintillation, and [ $^3$ H]-thymidine incorporation was calculated as cpm/ $10^4$  cells/hr.

IL-2R-positive T-cell blasts were prepared by stimulation of PBMCs with OKT3 for 3 days, after which the cells were washed and replaced in culture for an additional 11 days in the presence of 500 pM IL-2. The cells were subsequently washed and placed in culture in the absence of IL-2 for 36 hr, followed by a 12 hr stimulation with 50 ng/ml phorbol 12,13 dibutyrate (PdBu) to augment high-affinity IL-2R expression. Cells were washed free of PdBu and placed in culture for 12 hr prior to restimulation. Such

treatment enabled the generation of a G<sub>0</sub>/G<sub>1</sub>-synchronized cell population, made up of greater than 90% T8-positive T lymphocytes (Gullberg *et al.* (1986) J. Exp. Med. 163:270-284).

05 2. cDNA Library Construction

Human IL-2R-positive T-cell blasts were cultured in the presence of 1 nM IL-2, 10 mg/ml CHX, 250  $\mu$ M 4-thiouridine (Sigma Chemical Co., St. Louis, MO) and 2.5  $\mu$ Ci/ml [5,6-<sup>3</sup>H]-uridine (48 Ci/mmol, Amersham, 10 Arlington Heights, IL) for 2 hr. CHX was included in the 2 hr IL-2 stimulation of the IL-2R-positive, G<sub>0</sub>/G<sub>1</sub>-synchronized human T-cells from which the cDNA library was generated in order to isolate immediate-early genes, and also to possibly 15 superinduce the expression of low-abundance messages. Total RNA was isolated essentially as described by Caligiuri *et al.* (1989) J. Exp. Med. 171:1509-1526, and the 4-thiouridine-labelled RNA purified by passage over a phenylmercury agarose column as described by 20 Woodford *et al.* (1988) Anal. Biochem. 171:166-172). The cells were labelled with 4-thiouridine during stimulation, to enable isolation of only those transcripts which were synthesized during the period of IL-2 and CHX treatment (Stetler *et al.* (1984) Proc. 25 Nat. Acad. Sci. (USA) 81:1144-1148) and Woodford *et al.* (1988) Anal. Biochem. 171:166-172). Fractionation of total cellular RNA resulted in a 10-fold enrichment for newly-synthesized transcripts.

This thiol-selected RNA was used in the synthesis of Not-1 primer/adaptor-primed cDNA, utilizing the Riboclone cDNA Synthesis System (Promega, Madison, WI) according to manufacturers instructions. After  
05 addition of EcoRI adaptors (Promega), Not-1 digestion, and size selection for fragments greater than 500 base pairs (bp), the cDNA was ligated directionally into an EcoRI- and Not-1-digested pBluescript II SK+ plasmid vector (Stratagene, La Jolla, CA), followed by  
10 transformation into Epicurian Coli XL-1 Blue competent cells (Stratagene). A cDNA library of approximately 10,000 clones resulted.

### 3. Colony Screening

About 10% of the library was then screened using  
15 radiolabelled cDNA probes made from mRNA isolated from T-cells induced with IL-2 or from uninduced cells as follows. Single-stranded [<sup>32</sup>P]-labelled cDNA probes were prepared from poly(A)<sup>+</sup> RNA isolated from human T-cell blasts stimulated for 2 hr with medium  
20 (unstimulated probe), or 1 nM IL-2 and 10 µg/ml CHX (stimulated probe). Total cellular RNA was prepared as described by Caligiuri *et al.* (1989) J. Exp. Med. 171:1509-1526, and poly(A)<sup>+</sup> RNA was isolated by three passages over an oligo-dT-cellulose column (5 Prime-3  
25 Prime, West Chester, PA). First strand cDNA synthesis was performed with an oligo-dT 12-18 primer (United States Biochemical Corp., Cleveland, OH), using the Riboclone cDNA Synthesis System (Promega, Madison, WI) according to manufacturers instructions, with the  
30 exception of dCTP at a final concentration of 35 µM and the addition of 2.5 mCi/ml [<sup>32</sup>P]-dCTP.

Hybridization was carried out for 72-96 hr at 42°C in 50% formamide, with a final probe concentration of approximately  $2 \times 10^6$  cpm/ml (W. M. Strauss, in Current Protocols in Molecular Biology, (1989) pp. 6.3.1-6.3.6). Subsequent to hybridization, filters were washed repeatedly at 62°C in  $0.1 \times$  SSC ( $1 \times$  SSC = 0.15 M NaCl, 0.015 M sodium citrate, pH 7.0), 0.1% SDS and placed on film (Kodak XAR-5) with Dupont Cronex intensifying screens overnight at -70°C. The initial screening yielded 18 putative positive clones which exhibited differential hybridization to the stimulated and unstimulated probes after three independent screens. These clones were isolated for further characterization by Northern Blot analysis.

#### 4. Northern Blot Analysis

Total cellular RNA was isolated by the guanidine thiocyanate method described by Caligiuri et al. (ibid.), and denatured in glyoxal and DMSO. The RNA was fractionated on a 1% agarose gel in 0.01 M  $\text{NaH}_2\text{PO}_4$  with 0.5 mg/ml ethidium bromide (Selden, Current Protocols in Molecular Biology, (1989) pp. 4.9.5-4.9.8). To estimate sizes of RNA transcripts, a 0.24-9.5 kb RNA ladder (Bethesda Research Laboratories, Gaithersburg, MD) was run alongside the cellular RNA samples. After visualization under ultraviolet light, the RNA was transferred to nitrocellulose by capillary transfer in  $10 \times$  SSC. Plasmids were purified from the clones of interest, and the Not-I- and EcoRI-excised inserts [ $^{32}\text{P}$ ]-labelled with random primers. Hybridization was carried out in 50% formamide at 42°C for 48-72 hr,

followed by repeated washes in 0.1 X SSC, 0.1% SDS at 56-62°C (Selden, *ibid.*). Filters were exposed to Kodak XAR-5 film with Dupont Cronex intensifying screens, and specific bands quantitated with an EC  
05 densitometer (EC Apparatus Corp., St. Petersburg, FL).

In as much as CHX was included in both the library and probe preparation, it was essential to verify that the differential expression of putative clones observed upon colony screening was not due  
10 solely to the effects of this drug. In addition, determination of the sizes and patterns of induction of the RNA transcripts was necessary to enable estimation of the redundancy of the clones. Therefore, Northern blot analysis was performed with  
15 RNA isolated from human IL-2R-positive T-cell blasts stimulated with either CHX or IL-2 alone, or with a combination of the two agents.

Hybridization of the RNA with probes generated from the inserts of each of the 18 putative clones  
20 resulted in the identification of 4 clones that were solely CHX-induced. For the remaining 14 clones, the induction by the combination of IL-2 and CHX could not be accounted for by the effects of CHX alone. Based upon the patterns of induction and approximate sizes  
25 of the RNA transcripts, 8 readily distinguishable and apparently unique IL-2-induced genes were discerned among these 14. These are described in TABLE 1.



TABLE 1

<u>Clone</u>	<u>SEQ ID NO:</u>	<u>Insert (kb)</u>	<u>RNA (kb)</u>	<u>IL-2 Induction</u>
1A8	1	1.6	2.4	24
1F5	2, 3	1.1	0.6, 1.1	7
10A8	4, 5	2.0	2.2, 3.2	22
10D6	6, 7	1.0	3.5	6
10F9	8, 9	1.4	1.7	>50
11B2	10, 11	1.0	1.5	5
11E6	20	0.7	2.4	17
13E2	19	1.5	2.8	7

As shown in this Table and in FIG. 1, three of the genes, 1A8 (SEQ ID NO:1), 10A8 (SEQ ID NOS:4 and 5), and 10F9 (SEQ ID NOS:8 and 9), were induced by IL-2 alone, while five of the genes, 1F5 (SEQ ID NOS:2 and 3), 10D6 (SEQ ID NOS:6 and 7), 11B2 (SEQ ID NOS:10 and 11), 11E6 (SEQ ID NO:20), and 13E2 (SEQ ID NO:19), were induced by both CHX and IL-2. In several instances, the combination of IL-2 and CHX resulted in a marked synergistic induction.

## 5. Kinetic Analysis of IL-2-Induced Gene Expression

The temporal expression of the novel, IL-2-induced genes was determined by Northern blot analysis, using RNA isolated from human IL-2R-  
05 positive T-cell blasts after IL-2 stimulation in the presence or absence of CHX. Northern blots were prepared with 15 µg total RNA isolated from G<sub>0</sub>/G<sub>1</sub>-synchronized human T-cells stimulated for 0, 0.5, 1, 2, 4, or 8 hours with 1 nM IL-2 or IL-2 +  
10 10 µg/ml CHX. Filters were probed with the cDNA inserts of the IL-2-induced clones.

As shown in FIGS. 2A-2H, two of the genes, 1A8 (SEQ ID NO:1) (FIG. 2A) and 10D6 (SEQ ID NOS:6 and 7) (FIG. 2B), exhibited rapid induction, reaching peak  
15 levels within 1-4 hr of IL-2 stimulation and returning to basal levels after 8 hr, while the other six clones (FIGS. 2C-2H) remained at elevated levels for at least 8 hr after IL-2 treatment. The magnitude of IL-2 induction of steady state RNA  
20 levels of the clones ranged from an approximately 5-fold elevation of clone 11B2 (SEQ ID NOS:10 and 11) (FIG. 2F) to a greater than 50-fold stimulation of clone 10F9 (SEQ ID NOS:8 and 9) (FIG. 2E) during the interval examined. These results are also summarized  
25 in TABLE 1. Several of the clones were superinduced by CHX, with an increase observed in both the magnitude and duration of the IL-2 response.

The kinetics of induction of previously characterized IL-2-responsive genes have been found  
30 to range from those such as *c-fos*, which are rapidly and transiently induced within minutes of IL-2

stimulation (Dautry et al. (1988) J. Biol. Chem. 263:17615-17620), to those which remain at elevated levels through G<sub>1</sub> to S phase entry (Sabath et al. (1990) J. Biol. Chem. 265:12671-12678).

05 6. Sequence Analysis

To verify the redundancy of the clones as estimated from Northern analysis, as well as to determine the identities of the genes, the cDNA clones were subjected to sequence analysis.

10 Plasmids were isolated from the clones of interest essentially as described by Kraft et al. (1988) Biotechniques 6:544-547), and vector primers were used to sequence the termini of the cDNA inserts, employing the Sequenase 2.0 dideoxy  
15 sequencing kit (United States Biochemical, Cleveland, OH). Approximately 200 bases of sequence were attained from each end of the inserts. These partial sequences are set forth in the Sequence Listing as SEQ ID NOS: 1-19. Searches of the GenBank and EMBL  
20 data bases were performed with the FASTA program as described by Pearson et al. (1988) Proc. Natl. Acad. Sci. (USA) 85:2444-2448).

The combination of sequence and Northern analyses revealed that the 14 putative IL-2-induced  
25 clones consisted of 8 unique genes, three of which, (1A8 (SEQ ID NO:1), 11B2 (SEQ ID NOS:10 and 11), and 13E2 (SEQ ID NO:15), were isolated three times each. Searches of the GenBank and EMBL data bases with the partial sequences enabled the identification of one  
30 clone, 11E6 (SEQ ID NO:20), as pim-1, a previously

characterized IL-2-induced gene (Dautry *et al.* (1988) *J. Biol. Chem.* 263:17615-17620; and Kakut-Houri *et al.* (1987) *Gene* 54:105-111) which encodes a 33 kD cytoplasmic kinase (Telerman *et al.* (1988) *Mol. Cell. Biol.* 8:1498-1503). The others did not show significant homology to any known sequences.

Thus, by utilizing the method of the invention seven unique IL-2 induced genes were cloned, representing novel human genes. These clones were identified after screening only approximately 800 library colonies, and thus, it is estimated that as many as 80 additional novel IL-2-induced genes remain to be detected in the 10,000-clone library.

#### 7. Sensitivity of IL-2-Induced Gene Expression

As a further means of characterizing the regulation of expression of these genes, the sensitivity of induction to the known IL-2 functional antagonist was investigated. Human IL-2R-positive T-cell blasts were stimulated with IL-2 in the absence or presence of 0.5 mM dibutyryl-cAMP, a concentration of the membrane-permeant cAMP analog sufficient to inhibit IL-2-mediated G<sub>1</sub> progression without adversely affecting cellular viability. The effect of an equivalent molar amount of sodium butyrate, which does not inhibit the IL-2 response, was also tested to control for the actions of free butyric acid.

Northern blots were prepared as follows: Human IL-2R-positive T cells were treated with 1 nM IL-2 alone or in combination with 0.5 mM dibutyryl cAMP or sodium butyrate (NaBt) for 1, 2, or 4 hours. Filters

were prepared with 15 µg total RNA and hybridized with cDNA inserts or the IL-2 induced clones.

These analyses demonstrate that the IL-2 induction of one gene, 1A8 (SEQ ID NO:1) (FIG. 3A) is  
05 markedly inhibited when the intracellular level of cAMP is raised by the addition of dibutyryl cAMP, whereas the expression of two others, 10D6 (SEQ ID NOS:6 and 7) (FIG. 3B) and 13E2 (SEQ ID NO:15) (FIG. 3C), is augmented approximately 3-fold. By  
10 comparison, the expression of five of the genes was not affected by elevated cAMP (FIGS. 3D-3H). Thus, the sequences in clone 1A8 (SEQ ID NO:1) may be involved in T-cell proliferation. The fact that not all genes were sensitive to cAMP indicated that the  
15 observed results were not due to non-specific effects, and furthermore that the previously documented down-regulation of IL-2R binding capacity by cAMP (Johnson *et al.* (1990) *J. Immunol.* 145:1144-1151) could not account for the inhibition  
20 of gene expression.

#### 8. Responsive To T-cell Receptor Stimulation

In order to determine if activation of the T-cell receptor mediates the stimulation of expression of cytokine IL-2-induced genes, the  
25 following study was performed. Northern blots were prepared from 20 µg total cellular RNA isolated from human peripheral blood mononuclear cells (PBMCs) stimulated with a monoclonal antibody (OKT3) specific to the CD3 component of the T-cell antigen receptor  
30 complex. Blots were probed with cDNA inserts of the IL-2-induced clones. Data was determined as the mean  $\pm$  SEM (n=6).

By isolation of RNA at early time intervals, it was possible to identify those genes which were induced by T-cell receptor triggering in the absence of IL-2 effects. As shown in FIGS. 4A-4H, only one  
05 of the genes, 10D6 (SEQ ID NOS:6 and 7) exhibited heightened levels of expression after 2 hr of T-cell receptor activation, while the seven others were apparently insensitive to this stimulus. Two of the clones, 1F5 (SEQ ID NOS:2 and 3) and 11B2 (SEQ ID  
10 NOS:10 and 11), were undetectable, even after seven days of autoradiographic exposure of the Northern blots. Two other genes, 11E6 (SEQ ID NO:20) and 13E2 (SEQ ID NO:15), were expressed at relatively high levels regardless of the stimulus; activation with  
15 anti-CD3 did not induce RNA expression beyond the level observed by culture in medium alone. Identical results were obtained after 1 and 4 hr of stimulation.

To determine whether the cells were actually activated via CD3, aliquots of the cells were left in  
20 culture for 52 hr in the presence of 10 µg/ml CHX, alone, OKT3 alone, or OKT3 + CHX, after which cell cycle progression was monitored by [<sup>3</sup>H]-thymidine incorporation into RNA.

As shown in FIG. 5, the cells were sufficiently  
25 stimulated by anti-CD3. Thus, the T-cell receptor-induced expression of only one of the genes was comparable to that seen with IL-2 stimulation, while the expression of the seven others was unique to the IL-2 signaling pathway.

30 Thus, the methods described herein to identify IL-2-induced gene successfully selected and enriched for these genes that are highly specific for cytokine (IL-2) activation.

Of the 8 IL-2 induced G<sub>1</sub> progression genes reported here, only one appears to also be induced during the T cell receptor-mediated competence phase of the cell cycle. Thus, while several genes such as 05 c-fos, c-myc and c-raf-1 are known to be induced during both the initial G<sub>0</sub>-G<sub>1</sub> and subsequent G<sub>1</sub>-S phase transitions, the expression of a number of IL-2-stimulated genes is unique to the latter event. In addition, the immediate-early genes reported here 10 appear to define a class distinct from the IL-2-induced genes isolated by Sabath et al. (1990) J. Biol. Chem. 265:12671-12678). These investigators utilized a differential screening procedure to isolate genes expressed at the G<sub>1</sub>/S phase boundary in 15 a murine T helper clone which was stimulated with IL-2 for 20 hr in the absence of protein synthesis inhibitors. In this case, the expression of only 3 of the 21 clones isolated was inhibited by CHX, while the remainder were insensitive to this agent. This 20 pattern of regulation markedly contrasts with the CHX superinduction observed with the immediate-early IL-2-induced genes described here. Moreover, these observations indicate that IL-2 stimulates a complex program of gene expression, ranging from those genes 25 induced very early in G<sub>1</sub> through those subsequently expressed at the G<sub>1</sub>/S phase transition.

#### Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine 30 experimentation, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of this invention, and are covered by the following claims.

## SEQUENCE LISTING

- (1) GENERAL INFORMATION:
- (i) APPLICANT: Smith, Kendall A.
  - (ii) TITLE OF INVENTION: IL-2-Stimulated Gene Expression
  - 05 (iii) NUMBER OF SEQUENCES: 20
  - (iv) CORRESPONDENCE ADDRESS:
    - (A) ADDRESSEE: Lahive & Cockfield
    - (B) STREET: 60 State Street
    - (C) CITY: Boston
    - 10 (D) STATE: Massachusetts
    - (E) COUNTRY: U.S.A.
    - (F) ZIP: 02109
  - (v) COMPUTER READABLE FORM:
    - (A) MEDIUM TYPE: Floppy disk
    - 15 (B) COMPUTER: IBM PC compatible
    - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
    - (D) SOFTWARE: ASCII TEXT
  - (vi) CURRENT APPLICATION DATA:
    - (A) APPLICATION NUMBER:
    - 20 (B) FILING DATE:
    - (C) CLASSIFICATION:
  - (vii) PRIOR APPLICATION DATA:
    - (A) APPLICATION NUMBER: 07/796,066
    - (B) FILING DATE: 20-NOVEMBER-1991
    - 25 (C) CLASSIFICATION:
  - (viii) ATTORNEY/AGENT INFORMATION:
    - (A) NAME: DeConti, Giulio A. Jr.
    - (B) REGISTRATION NUMBER: 31,503
    - (C) REFERENCE/DOCKET NUMBER: DCI-028PC
  - 30 (ix) TELECOMMUNICATION INFORMATION:
    - (A) TELEPHONE: 617-227-7400
    - (B) TELEFAX: 617-227-5941



- (2) INFORMATION FOR SEQ ID NO:1:
- (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 1562 base pairs
    - (B) TYPE: nucleic acid
    - 05 (C) STRANDEDNESS: single stranded
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: cDNA
  - (iii) HYPOTHETICAL: no
  - (iv) ANTI-SENSE: no
  - 10 (vi) ORIGINAL SOURCE:
    - (A) ORGANISM: human
    - (G) CELL TYPE: T-cell blast
  - (vii) IMMEDIATE SOURCE:
    - (A) LIBRARY:
    - 15 (B) CLONE: 1A8-T7
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

TGCGCTCCAG CAGCCTGTTT GGGAAGCAGC AGTCTCTCCT	40
TCAGATACTG TGGGACTCAT GCTGGAGAGG AGCCGCCCCAC	80
TTCCAGGACC TGTGAATAAG GGCTAATGAT GAGGGTTGGT	120
GGGGCTCTCT GTGGGGCAAA AAGGTGGTAT GGGGGTTAGC	160
ACTGGCTCTC GTTCTCACCG GAGAAGGAAG TGTTCTAGTG	200
TGGTTTAGGA AACATGTGGA TAAAGGGAAC CATGAAAATG	240
AGAGGAGGAA AGACATCCAG ATCAGCTGTT TTGCCTGTTG	280
CTCAGTTGAC TCTGATTGCA TCCTGTTTTT CTAATTCCCA	320

	GACTGTTCTG GGCACGGAAG GGACCCTGGA TGTGGAGTCT	360
	TCCCCTTTGG CCCTCCTCAC TGGCCTCTGG GCTAGCCAGA	400
	GTCCCTTAGC TTGTACCTCG TAACACTCCT GTGTGTCTGT	440
	CCAGCCTTGC AGTCATGTCA AGGCCAGCAA GCTGATGTGA	480
05	CTCTGCCATG CGAGATATTA TACCTCAAAC ACTGGCCTGT	520
	GAGCCCTTTC CAAGTCAGTG GAGAGCCCTG AAAGGAGCCT	560
	CACTTGAATC CAGCTCAGTG CTCTGGGTGG CCCCCTGCAG	600
	GTGGCCCCTG ACCCTGCGTT GCAGCAGGGT CCACCTGTGA	640
	GCAGGCCCCG CCTGGGGCCT CTTCTGGAT GTGCCCTCTC	680
10	TGAGTTCTGT GCTGTCTCTT GGAGGCAGGG CCCAGGAGAA	720
	CAAAGTGTGG AGGCCTCGGG GAGTGGCTTT TCCAGCTCTC	760
	ATGCCCCGCA GTGTGGAACA AGGCAGAAAA GGATCCTAGG	800
	AAATAAGTCT CTTGGCGGTC CCTGAGAGTC CTGCTGAAAT	840
	CCAGCCAGTG TTTTGTGG TATGAGAACA GGCAAAAAGA	880
15	GATGCCCCGA GATAGAAGGG GAGCCTTG TG TTTCTTTCCT	920
	GCAGACGTGA GATGAACACT GGAGTGGGCA GAGGTGGCCC	960
	AGGACCATGC ACCTTAGAGT GCAGAGCTGG GGGGAGAGGC	1000

	TGCTTCGAAG GGCAGGACTG GGGATAATCA GAACCTGCCT	1040
	GTCACCTCAG GGCATCACTG AACAAACATT TCCTGATGGG	1080
	AACTCCTGCG CAGAGCCCAG GCTGGGGAAG TGAACCTACCC	1120
	AGGGCAGCCC CTTTGTGGCC CAGGATAATC AACACTGTTC	1160
05	TCTCTGTACC ATGAGCTCCT CCAGGAGATT ATTTAAGTGT	1200
	ATTGTATCAT TGGTTTTCTG TGATTGTCAT AACATTGTTT	1240
	TTGTTATTGT TGGTGCTGTT GTTATTTATT ATTGTAATTT	1280
	CAGTTTGCCT CTA CTG GAGA ATCTCAGCAG GGGTTTCAGC	1320
	CTGACTGTCT CCCTTTCTCT ACCAGACTCT ACCTCTGAAT	1360
10	GTGCTGGGAA CCTCTTGGAG CCTGTCAGGA ACTCCTCACT	1400
	GTTTAAATAT TTATTTATTG TGACAAATGG AGCTGGTTTC	1440
	CTAGATATGA ATGATGTTTG CAATCCCCAT TTCCTGTTT	1480
	CAGCATGTTA TATTCTTATA AAATAAAAGC AAAAGTCAAA	1520
	TATGAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA	1560
15	AA	1562

- (2) INFORMATION FOR SEQ ID NO:2:
- (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 188 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: single stranded
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: cDNA
  - (iii) HYPOTHETICAL: no
  - (iv) ANTI-SENSE: no
  - (vi) ORIGINAL SOURCE:
    - (A) ORGANISM: human
    - (G) CELL TYPE: T-cell blast
  - (vii) IMMEDIATE SOURCE:
    - (A) LIBRARY:
    - (B) CLONE: 1F5
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

TATTAGACCT CTCAGGTAGC AGCTGAGACA TTGTATCCAG	40
TTTCCTGATT GTTTTCAATG GAATAATCAT GTATACATGC	80
ACTACTAATG AGACAATGGT GATTCTAAAA GCTTAATCAG	120
GGGGACTTTT GTGTATTCCA AATCTACTAA AAATAAAGAA	160
ACACAGAAAT GAGAAAAAAA AAAAAAAA	188

- (2) INFORMATION FOR SEQ ID NO:3:
- (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 163 base pairs
    - (B) TYPE: nucleic acid
    - 05 (C) STRANDEDNESS: single stranded
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: cDNA
  - (iii) HYPOTHETICAL: no
  - (iv) ANTI-SENSE: no
  - 10 (vi) ORIGINAL SOURCE:
    - (A) ORGANISM: human
    - (G) CELL TYPE: T-cell blast
  - (vii) IMMEDIATE SOURCE:
    - (A) LIBRARY:
    - 15 (B) CLONE: 1F5-T7
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATTTAGAGCA	ACTCAGGAAA	TAGGTGCACA	CAAGCAAACC	40
ATGTGGTTAA	AGCCTTTGGA	ACTGGTTTGA	GCAAAGCTGT	80
AGGTGATTG	ACAAAATCAT	CTGCAAACC	AGATTCTAA	120
20 CACTCCTGCT	GTGTATCTCA	TTCTGCTGAT	GTGTGTGCTC	160
ATA				163

- (2) INFORMATION FOR SEQ ID NO:4:
- (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 199 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: single stranded
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: cDNA
  - (iii) HYPOTHETICAL: no
  - (iv) ANTI-SENSE: no
  - (v) ORIGINAL SOURCE:
    - (A) ORGANISM: human
    - (G) CELL TYPE: T-cell blast
  - (vii) IMMEDIATE SOURCE:
    - (A) LIBRARY:
    - (B) CLONE: 10A8
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

	GTTTGACTCA TCTTATATGG GAAACCATGT AGCAGTGAGT	40
	CATATCTTAA TATATTTCTA AATGTTTGGC ATGTAAACGT	80
	AAACTCAGCA TNAAAATATT TCAGTGAATT TGCAGTGT	120
20	AATCATAGTT ACTGTGTAAA CTCATCTGAA ATGTTACAAA	160
	AATAAACTAT AAAACAAAAA TTTGAAAAAA AAAAAAAAAA	199

- (2) INFORMATION FOR SEQ ID NO:5:
- (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 182 base pairs
    - (B) TYPE: nucleic acid
    - 05 (C) STRANDEDNESS: single stranded
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: cDNA
  - (iii) HYPOTHETICAL: no
  - (iv) ANTI-SENSE: no
  - 10 (vi) ORIGINAL SOURCE:
    - (A) ORGANISM: human
    - (G) CELL TYPE: T-cell blast
  - (vii) IMMEDIATE SOURCE:
    - (A) LIBRARY:
    - 15 (B) CLONE: 10A8-T7
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

TCTCCCTGCT CTTCTGCTCG CTGCCGCTGC TGGACTATGG	40
GCAGTACGTC CAGTACTGCC GGGACCTGGT GCTTCATCCG	80
GCACGGCGGA CCGCTTACCT GCAGCTGTAC GCCACCCTGC	120
20 TGCTGCTTCT CATTGTCTCG GTGCTCGCCT GCAACTTCAG	160
TGTCATTCTC AACTCATCCG CA	182

- (2) INFORMATION FOR SEQ ID NO:6:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 249 base pairs
- (B) TYPE: nucleic acid
- 05 (C) STRANDEDNESS: single stranded
- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: no
- (iv) ANTI-SENSE: no
- 10 (vi) ORIGINAL SOURCE:
- (A) ORGANISM: human
- (G) CELL TYPE: T-cell blast
- (vii) IMMEDIATE SOURCE:
- (A) LIBRARY:
- 15 (B) CLONE: 10D6
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TTCCTCTGTT TTACAACTG CTTGGCAGCC CCAGGTGAAG 40

CATCAAGGAT TGTTTGGTAT TAAATTTGT GTTCACGGGA 80

TGCACCAAAG TGTGTACCCC GTAAGCATGA AACCAGTGTT 120

20 TTTTGT TTTT TAGTTC TTATTCCGGA GCCTCAAACA 160

AGCATTATAC CTTCTGTGAT TATGATTTCC TCTCCTATAA 200

TTATTTCTGT AGCACTCCAC ACTGATCTTT GGAAACTTGC 240

CCCTTATTT 249



- (2) INFORMATION FOR SEQ ID NO:7:
- (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 201 base pairs
    - (B) TYPE: nucleic acid
    - 05 (C) STRANDEDNESS: single stranded
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: cDNA
  - (iii) HYPOTHETICAL: no
  - (iv) ANTI-SENSE: no
  - 10 (vi) ORIGINAL SOURCE:
    - (A) ORGANISM: human
    - (G) CELL TYPE: T-cell blast
  - (vii) IMMEDIATE SOURCE:
    - (A) LIBRARY:
    - 15 (B) CLONE: 10D6-T7
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CCGTTGCTGT CGCACGGTGG CCTCTCCAGC AGAGTCAGAT	40
GAGGAAAACC GACAGAAGAC CCGGCCACGA AAAAAATTT	80
CAGTGAAGC CTTGGGAATC CTCCAGAGTT TCATACAAGA	120
20 CGTGGGCCTG TACCCTGACG AAGAGGCCAT CCAGACTCTG	160
TCTGCCCAGC TCGACCTTCC CAAGTNNCAT CATCAAGTTC	200
T	201

- (2) INFORMATION FOR SEQ ID NO:8:
- (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 397 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: single stranded
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: cDNA
  - (iii) HYPOTHETICAL: no
  - (iv) ANTI-SENSE: no
  - (vi) ORIGINAL SOURCE:
    - (A) ORGANISM: human
    - (G) CELL TYPE: T-cell blast
  - (vii) IMMEDIATE SOURCE:
    - (A) LIBRARY:
    - (B) CLONE: 10F9-T3
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

	ATATTGGAGA TGACACTACA TAGTAGAAAT GCAGCCGGAG	40
	CCTCAGTCCC CAGCAGAGCC TGTGTCTCAC CCCCTCACAG	80
	GACAGAGCTG TATCTGCATG AGCTGGTCTC ACTGTGGCGC	120
20	AGGCCCGGGG GGAGTGCCTT GGCTGTCAGA GANNNTGCTG	160
	GTTTGAGGCC ACCACTGCAG TCTGCTAGGT CTGCTCCTGC	200
	CCAGGAAGGT GCCTGCACAT GAGAGGAGAG AAATACACGT	240
	CTGATAAGAC TTCATGAAAT AATAATTATA GCAAAGAACA	280

GTTTGGTGGT CTTTTCTCTT CCCTGATTTT TCTGTAATTG 320  
ACATTATACC TTTATTACCT CTTTATTTTA TTACCTCTAT 360  
AATAAAATGA TACCTTTTCAT GTAAAAA AAAA 397

(2) INFORMATION FOR SEQ ID NO:9:

- 05 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 199 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single stranded  
(D) TOPOLOGY: linear  
10 (ii) MOLECULE TYPE: cDNA  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: no  
(v) ORIGINAL SOURCE:  
(A) ORGANISM: human  
15 (G) CELL TYPE: T-cell blast  
(vii) IMMEDIATE SOURCE:  
(A) LIBRARY:  
(B) CLONE: 10F9-T7  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

20 TTGCTGTCGG CAGTGCCCGC AGCCTGCAAC ACCTGTGCCG 40  
CCTTGTCATC AACCGTCTGG TGGCCGACGT GGACTGCCTG 80  
CCACTGCCAC TGCCCCGGCG CATGGCCGAC TACCTCCGAC 120  
AGTACCCCTT CCAGCTCTGA CTGTACGGGG CAATTGCACC 160  
CTCACCCAGT CGCACCTGGA GGACATCAGC CAGCTGACT 199

- (2) INFORMATION FOR SEQ ID NO:10:
- (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 385 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: single stranded
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: cDNA
  - (iii) HYPOTHETICAL: no
  - (iv) ANTI-SENSE: no
  - (vi) ORIGINAL SOURCE:
    - (A) ORGANISM: human
    - (G) CELL TYPE: T-cell blast
  - (vii) IMMEDIATE SOURCE:
    - (A) LIBRARY:
    - (B) CLONE: 11B2
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

CGCTGAACTG CAGGCGGGGG GGGCGCCTGA GAGCGAGAGC	40
GCGGCTCCCG AGGAGGGGCC CGGTGGCGCA GGGCCAGGCT	80
GGTCCGAGCT GAGGACTCTG CAAGTGTCTG GAGCGCTGCT	120
CGCCCAGGAA GGCCTAGGCT AGACGTGNNC TCAGGCNNNN	160
ANNGACAGAC TGNNGGGGCA GGCCTGACTC AGCAGCTGCG	200
CTCGGGCAGG AAAGGCAGGA AAGGAGCGGC GCCCTGGACT	240
TGGTACAGTT GCAGGAGCGT GAAGGACTTA GCCGACTGCG	280

CTGCTTTTTC AAAACGGATC CGGGCAATGC TTCGTTTCT 320  
AAAGGATGCT GCTGTTGAAG CTTTGAATTT TACAATAAAC 360  
TTTTTGAAAC AAAAAAAAAA AAAAA 385

- (2) INFORMATION FOR SEQ ID NO:11:
- 05 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 204 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single stranded  
(D) TOPOLOGY: linear
- 10 (ii) MOLECULE TYPE: cDNA  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: no  
(v) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(G) CELL TYPE: T-cell blast
- 15 (vii) IMMEDIATE SOURCE:  
(A) LIBRARY:  
(B) CLONE: 11B2-T7  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

20 CATCGCGCTG CAGATCCATT TTACGCTGAT CCAGGCTTCT 40  
GCTGCGAGAA CGACATCGAC ATAGTGC GCG TGGGCGATGT 80

GCAGCGGCTG GCGGCTATCG TGGNCNCGGC GAAGGAGGCG 120  
GGTNNNNCGA CCTGCACTGC ATCCTCATTT CGAACCCAAC 160  
GAGGACNCCT GGAAGATCCC GCCTTGGAGA AGCTCAGCCT 200  
GTTT 204

- 05 (2) INFORMATION FOR SEQ ID NO:12:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 320 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single stranded  
10 (D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: cDNA  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: no  
(vi) ORIGINAL SOURCE:  
15 (A) ORGANISM: human  
(G) CELL TYPE: T-cell blast  
(vii) IMMEDIATE SOURCE:  
(A) LIBRARY:  
(B) CLONE: 1G9-T3  
20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

CCGAGACCTG CATTGTCTCC TGTCACGAAC CCTCACACGG 40  
ACGCCTGGAA GAGCCACGGC TTGGTGGAGG AGGCCAGCTA 80  
CTGCGAAGAA AGCCGGAACA ACCAGTGGGT CCCCTACATC 120  
TCTCTTCAGG AACGCTGAGG CCCTTCCCAG CAGCAGAATC 160

TGTTGAGTTG CTGCCACAAA GAAAAAATAC AATAAATATT 200  
TGAACCCCTT GGGCCCCAGC ACAACCCCCC CAAAACAACC 240  
CAACCCACGA GGACCATCGG GGGCAGAGTC GTTGGAGACT 280  
GAAGAGGAAG AGGAGGAGGA GAAGGGGAGT GAGCGGCCGC 320

- 05 (2) INFORMATION FOR SEQ ID NO:13:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 227 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single stranded  
10 (D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: cDNA  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: no  
(vi) ORIGINAL SOURCE:  
15 (A) ORGANISM: human  
(G) CELL TYPE: T-cell blast  
(vii) IMMEDIATE SOURCE:  
(A) LIBRARY:  
(B) CLONE: 1G9-T7  
20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

TCGCCCTGCA AATCCACTTC ACGCTCATCC AGTCCTTCTG 40  
CTGTGACAAC GACATCAACA TCGTGCGGGT GTCGGGCATG 80

CAGCGCCTGG CGAGCTCCTG GGAGAGCCGG CCGAGACCCA 120  
GGGCACCACC GAGGCCCGAG ACCTGCATTG TCTCCTGGTC 160  
ACGAACCCTC ACACGGANNC CTGGAAGAGC CACGGCTTGG 200  
TGGAGNNNNC CAGCTACTGC GAAGAAA 227

- 05 (2) INFORMATION FOR SEQ ID NO:14:  
(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 150 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single stranded  
10 (D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: cDNA  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: no  
(v) ORIGINAL SOURCE:  
15 (A) ORGANISM: human  
(G) CELL TYPE: T-cell blast  
(vii) IMMEDIATE SOURCE:  
(A) LIBRARY:  
(B) CLONE: 3B2-T7  
20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

CCGTTGCTGT CGCCAGCATC ACCCTCCCCG AGTGACAGCC 40  
CGGCGGGACC TTGGTCTGAT CGACGTGGTG ACGCCCCGGG 80  
GCCTAGAGCG GGCTGGCTCT GTGGAGGGGC CCTCCGAGGG 120  
TGCCGAGTGC GGCGTGGAGA CTGGCAGGCG 150



- (2) INFORMATION FOR SEQ ID NO:15:
- (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 184 base pairs
    - (B) TYPE: nucleic acid
    - 05 (C) STRANDEDNESS: single stranded
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: cDNA
  - (iii) HYPOTHETICAL: no
  - (iv) ANTI-SENSE: no
  - 10 (vi) ORIGINAL SOURCE:
    - (A) ORGANISM: human
    - (G) CELL TYPE: T-cell blast
  - (vii) IMMEDIATE SOURCE:
    - (A) LIBRARY:
    - 15 (B) CLONE: 13E2
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

GGAGGGCTGC GACGCTTGCT CTGTTTGTGG GGTGACGGGA	40
CTCAGGCGGG ACAGTGCTGC AGCTCCCTGG CTTCTGTGGG	80
NCCCCTCACC TACTTACCCA GGTGGGTCCC GGCTCTGTGG	120
20 GTGATGGGGA GGGGCATTGC TGA CTGTGTA TATAGGATAA	160
TTATGAAAAG CAGTTCTGGA TGGT	184

- (2) INFORMATION FOR SEQ ID NO:16:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 198 base pairs
- (B) TYPE: nucleic acid
- 05 (C) STRANDEDNESS: single stranded
- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: no
- (iv) ANTI-SENSE: no
- 10 (vi) ORIGINAL SOURCE:
- (A) ORGANISM: human
- (G) CELL TYPE: T-cell blast
- (vii) IMMEDIATE SOURCE:
- (A) LIBRARY:
- 15 (B) CLONE: 8D4-T3
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

CCGAGCAGCT TTTCAAATG CACTATGCCT GATTGCTGAT 40

CGTGTTTTAA CTTTTCTTT TCCIGTTTTT ATTTTGGTAT 80

TAAGTCGTTG CCTTTATTTG TAAAGCTGTT ATAAATATAT 120

20 ATTATATAAA TATATTAAAA AGGAAAATGT TTCAGAAAAA 160

AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 198

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 173 base pairs

(B) TYPE: nucleic acid

05 (C) STRANDEDNESS: single stranded

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: no

(iv) ANTI-SENSE: no

10 (vi) ORIGINAL SOURCE:

(A) ORGANISM: human

(G) CELL TYPE: T-cell blast

(vii) IMMEDIATE SOURCE:

(A) LIBRARY:

15 (B) CLONE: 8D4-T7

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GCGTGTTGGT ATAGGACTTT AAAGCTCCTT TTGGCATAGG 40

GAAGTCACGA AGGATTGCTT GACATCAGGA GACTTGGGGG 80

GATTGTAGCA GACGTCTTGG GCTTTNNNCC ACCCAGAGAA 120

20 TAGCCCCCTT CGATACACAT CANTGGATTT TCAAAANTTC 160

AAAGTCTTGG TCT 173

- (2) INFORMATION FOR SEQ ID NO:18:
- (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 176 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: single stranded
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: cDNA
  - (iii) HYPOTHETICAL: no
  - (iv) ANTI-SENSE: no
  - (vi) ORIGINAL SOURCE:
    - (A) ORGANISM: human
    - (G) CELL TYPE: T-cell blast
  - (vii) IMMEDIATE SOURCE:
    - (A) LIBRARY:
    - (B) CLONE: 8G8-T7
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

	GCGTGTGGT ATAGGACTTT AAAGCTCCTT TTGGCATAGG	40
	GAAGTCACGA AGGATTGCTT GACATCAGGA GACTTGGGGG	80
	GGATTGTAGC AGACGTCTGG GCTTTNNNCC CACCCAGAGA	120
20	ATANNNCCCT TCGATACACA TCAGCTGGAT TTTCAAAGC	160
	TTCAAAGTCT TGGTCT	176

- (2) INFORMATION FOR SEQ ID NO:19:
- (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 194 base pairs
    - (B) TYPE: nucleic acid
    - 05 (C) STRANDEDNESS: single stranded
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: cDNA
  - (iii) HYPOTHETICAL: no
  - (iv) ANTI-SENSE: no
  - 10 (v) ORIGINAL SOURCE:
    - (A) ORGANISM: human
    - (G) CELL TYPE: T-cell blast
  - (vii) IMMEDIATE SOURCE:
    - (A) LIBRARY:
    - 15 (B) CLONE: 13E2-T7
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

	CACGAAGGAT TGCTTGACAT CAGGAGACTT GGGGGGGATT	40
	GTAGCAGACG TCTGGGCTTT TCCCCACCCA GAGAATAGCC	80
	CCCTTCGATA CACATCAGCT GGATTTTCAA AAGCTTCAAA	120
20	GTCTTGGTCT GTGAGTCACT CTTCAAGTTTG GGAGCTGGGT	160
	CTGTGGCTTG ATCAGAGTAC TTCAAAGAGG CTTC	194

## (2) INFORMATION FOR SEQ ID NO:20:

- 05 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 195 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single stranded  
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA  
(iii) HYPOTHETICAL: no  
(iv) ANTI-SENSE: no  
10 (vi) ORIGINAL SOURCE:  
(A) ORGANISM: human  
(G) CELL TYPE: T-cell blast  
(vii) IMMEDIATE SOURCE:  
(A) LIBRARY:  
15 (B) CLONE: 11E6-T3  
(ix) FEATURE:  
(A) NAME/KEY: pim-1  
(C) IDENTIFICATION METHOD: sequence  
analysis and comparison with published  
sequence  
20 (x) PUBLICATION INFORMATION:  
(A) AUTHORS: Zakut-Houri, R.  
Huzum, S.  
Girol, D.  
Telerman, A.  
25 (B) TITLE: The cDNA Sequence and Gene  
Analysis of the Human pim  
Oncogene  
(C) JOURNAL: Gene  
(D) VOLUME: 54  
30 (E) ISSUE:  
(F) PAGES: 105-111  
(G) DATE: 1987  
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

	ATTGCTGACT GTGTATATAG GATAATTATG AAAAGCAGTT	40
.	CTGGATGGTG TGCCTTCCAG ATCCTCTCTG GGGNTGTGTT	80
.	TTGAGCAGCA GGTAGCCTGC TGGTTTTATC TGAGTGAAAT	120
	ACTGTACAGG GGNATAAAAG AGATCTTATT TTTTTTTTAA	160
05	TACTTGGCGT TTTTGAATA AAAACCTTTT GTCTT	195

CLAIMS

1. A method of producing a complementary DNA (cDNA) library enriched in ligand-inducible genes of a cell, said method comprising the steps of:
  - 05 (a) activating a cellular ligand receptor for a predetermined period of time in the presence of:
    - (i) labelled RNA precursors which are incorporated into the RNA synthesized by said cell in response to receptor
    - 10 (ii) a substance which enhances the level of RNA in said cell;
  - (b) separating the labelled RNA from unlabelled RNA;
  - 15 (c) preparing cDNA from said labelled RNA;
  - (d) cloning said cDNA in host cells to provide a first cDNA library of cDNA-containing clones;
  - (e) screening said first library for clones containing genes induced by said ligand; and
  - 20 (f) selecting said clones containing said ligand-inducible genes to produce a second cDNA library enriched in ligand-inducible genes.
2. The method of claim 1 wherein said activating  
25 step (a) comprises exposing said cell to a ligand which binds said receptor, said ligand being at a level effective to activate said receptor.



3. The method of claim 2 wherein said activating step (a) comprises activating said receptor by exposing said cell to a ligand selected from the group consisting of cytokines, antibodies,  
05 peptides, and receptor-binding fragments thereof.
4. The method of claim 3 wherein said activating step (a) comprises treating said cell with a cytokine selected from the group consisting of the interleukins, cellular growth factors, and  
10 colony stimulating factors, and hormones.
5. The method of claim 4 wherein said activating step (a) comprises treating said cell with interleukin-2 (IL-2).
6. The method of claim 1 wherein said activating  
15 step (a) comprises activating said receptor in the presence of radiolabelled nucleoside 5'-triphosphates and thiol-labelled nucleoside 5'-triphosphates.
7. The method of claim 1 wherein said activating  
20 step (a) comprises activating said receptor in the presence of labelled RNA precursors selected from the group consisting of tritiated uridine, 4-thiouridine, 6-thioguanosine, and combinations thereof.
- 25 8. The method of claim 1 wherein said activating step (a) comprises activating said receptor in the presence of a substance which enhances the level of RNA, said substance being an inhibitor of protein synthesis.

9. The method of claim 8 wherein said activating step (a) comprises activating said receptor in the presence of an inhibitor of protein synthesis selected from the group consisting of puromycin, cyclohexamide, and mixtures thereof.
- 05
10. The method of claim 1 wherein said activating step (a) comprises activating said receptor in the presence of a substance which enhances the level of RNA selected from the group consisting of cyclic adenosine monophosphate (cAMP), an analog thereof, and molecules which increase the intracellular level of cAMP.
- 10
11. The method of claim 10 wherein said activating step (a) comprises activating said receptor in the presence of dibutyryl cAMP.
- 15
12. The method of claim 1 wherein said separating step (b) comprising separating said labelled RNA from said unlabelled RNA by affinity chromatography.
- 20
13. The method of claim 12 wherein said activating step (a) comprises activating said receptor in the presence of thiol-labelled RNA precursors, and said separating step (b) comprises:
- 25
- (i) extracting cellular RNA from said activated cell;

- 05 (ii) contacting said cellular RNA with  
phenylmercury agarose under conditions  
conducive for the binding of said  
thiol-labelled RNA to said agarose  
phenylmercury;
- (iii) removing any unbound RNA; and
- (iv) eluting the bound, thiol-labelled RNA  
from the phenylmercury agarose under  
reducing conditions.
- 10 14. The method of claim 1 wherein said screening step  
(e) comprises probing said first cDNA library  
with:
- 15 (i) a DNA probe constructed from messenger  
RNA (mRNA) derived from a  
receptor-activated cell; and
- (ii) a DNA probe constructed from mRNA  
derived from an unactivated cell,  
said first library being probed under conditions  
such that said DNA probes hybridize specifically  
20 with complementary cDNA sequences in said  
library; and
- said selecting step (f) comprises selecting the  
clones in said first library containing cDNA  
sequences that hybridize only with said probes  
25 constructed from said activated cell mRNA, to  
prepare a second cDNA library of clones enriched  
in ligand-inducible genes.

15. The method of claim 1 wherein said screening step (e) comprises:
- 05 (i) probing said first cDNA library with an excess of RNA obtained from an uninduced cell under conditions such that said RNA hybridize specifically with complementary cDNA sequences in said first library; and
  - 10 (ii) removing the clones from said first library containing cDNA which hybridizes to said RNA from said uninduced cell, leaving clones containing cDNA common to only said ligand-induced cell.
16. A method of producing a complementary DNA (cDNA) library enriched for ligand-inducible genes of a cell, said method comprising the steps of:
- 15 (a) activating an interleukin-2 receptor (IL-2R) on a cell by exposing said cell with IL-2 for a predetermined period in the presence of thiol-labelled RNA precursors, radiolabelled RNA precursors, and cyclohexamide;
  - 20 (b) separating the labelled RNA transcribed during the period of exposure to IL-2 from unlabelled RNA by affinity chromatography using phenylmethyl mercury agarose;
  - 25 (c) preparing cDNA from said labelled RNA;
  - (d) cloning said cDNA in host cells to produce a first cDNA library and
  - 30 (e) screening said first library for clones expressing genes activated by said ligand by probing said library with:

- (i) a DNA probe constructed from messenger RNA (mRNA) derived from a receptor-activated cell; and
- (ii) a DNA probe constructed from mRNA derived from an unactivated cell, said library being probed under conditions such that said DNA probes hybridize specifically with complementary cDNA sequences in said library
- (f) selecting the clones in said library containing cDNA sequences that hybridize only with said probes constructed from said activated cell mRNA, to produce a second cDNA library enriched in ligand-inducible genes.
- 15 17. A method of selecting for, isolating, and identifying a ligand-inducible gene in a cell, comprising the steps of:
- (a) preparing a cDNA library enriched for said ligand-inducible genes according to claim 1; and
- (b) identifying the genes from which said labelled RNA was transcribed in response to ligand induction.

18. The method of claim 17 wherein said identifying step (b) comprises:
- (i) preparing a cDNA library from said labelled RNA;
  - 05 (ii) probing said library with a DNA probe constructed from said labelled RNA under conditions such that said probe hybridizes with complementary cDNA sequences in said library; and
  - 10 (iii) determining the sequence of said cDNA to which said DNA probe hybridizes.
19. A method of selecting for, isolating, and identifying a ligand-inducible gene in a cell, comprising the steps of:
- 15 (a) activating a cellular receptor for the ligand for a predetermined period of time in the presence of:
    - (i) labelled RNA precursors which are incorporated into the RNA synthesized by the cell in response to receptor activation; and
    - 20 (ii) a substance which enhances the level of RNA in said cell;
  - 25 (b) separating the labelled RNA from unlabelled RNA; and
  - 30 (c) identifying the gene from which said labelled RNA was transcribed by hybridizing said labelled RNA to a DNA probe whose sequence is known, under conditions conducive for hybridization, and then determining the sequence of said labelled RNA to which said known DNA probe has hybridized.

20. A cDNA library enriched for genes whose expression is induced by ligand activation, said library being constructed from labelled mRNA transcribed in a cell in response to ligand activation.
21. The cDNA library of claim 20 wherein said library is constructed from mRNA in the presence of an RNA potentiator.
22. The cDNA library of claim 20 wherein said library is constructed from thiol-labelled mRNA.
23. A cDNA library of claim 20 wherein said library is constructed from mRNA transcribed in response to IL-2R activation of the interleukin-2 receptor (IL-2R).
24. The cDNA library of claim 23 wherein said library is constructed from thiol-labelled mRNA transcribed in the presence of cyclohexamide.
25. A gene expressed as a consequence of a ligand-receptor interaction and included in said cDNA library of claim 20, said gene comprising the DNA sequence set forth in the Sequence Listing as SEQ ID NO:1.
26. A gene expressed as a consequence of a ligand-receptor interaction and included in said cDNA library of claim 20, said gene comprising the DNA sequence set forth in the Sequence Listing as SEQ ID NO:2.

27. A gene expressed as a consequence of a  
ligand-receptor interaction and included in said  
cDNA library of claim 20, said gene comprising  
the DNA sequence set forth in the Sequence  
Listing as SEQ ID NO:3.  
05
28. A gene expressed as a consequence of a  
cytokine-receptor interaction and included in  
said cDNA library of claim 20, said gene  
comprising the DNA sequence set forth in the  
Sequence Listing as SEQ ID NO:4.  
10
29. A gene expressed as a consequence of a ligand-  
receptor interaction and included in said cDNA  
library of claim 20, said gene comprising the DNA  
sequence set forth in the Sequence Listing as SEQ  
ID NO:5.  
15
30. A gene expressed as a consequence of a ligand-  
receptor interaction and included in said cDNA  
library of claim 20, said gene comprising the DNA  
sequence set forth in the Sequence Listing as SEQ  
ID NO:6.  
20
31. A gene expressed as a consequence of a ligand-  
receptor interaction and included in said cDNA  
library of claim 20, said gene comprising the DNA  
sequence set forth in the Sequence Listing as SEQ  
ID NO:7.  
25




32. A gene expressed as a consequence of a ligand-receptor interaction and included in said cDNA library of claim 20, said gene comprising the DNA sequence set forth in the Sequence Listing as SEQ ID NO:8.
- 05
33. A gene expressed as a consequence of a ligand-receptor interaction and included in said cDNA library of claim 20, said gene comprising the DNA sequence set forth in the Sequence Listing as SEQ ID NO:9.
- 10
34. A gene expressed as a consequence of a ligand-receptor interaction and included in said cDNA library of claim 20, said gene comprising the DNA sequence set forth in the Sequence Listing as SEQ ID NO:10.
- 15
35. A gene expressed as a consequence of a ligand-receptor interaction and included in said cDNA library of claim 20, said gene comprising the DNA sequence set forth in the Sequence Listing as SEQ ID NO:11.
- 20
36. A gene expressed as a consequence of a ligand-receptor interaction and included in said cDNA library of claim 20, said gene comprising the DNA sequence set forth in the Sequence Listing as SEQ ID NO:12.
- 25

- 05 37. A gene expressed as a consequence of a ligand-receptor interaction and included in said cDNA library of claim 20, said gene comprising the DNA sequence set forth in the Sequence Listing as SEQ ID NO:13.
- 10 38. A gene expressed as a consequence of a ligand-receptor interaction and included in said cDNA library of claim 20, said gene comprising the DNA sequence set forth in the Sequence Listing as SEQ ID NO:14.
- 15 39. A gene expressed as a consequence of a ligand-receptor interaction and included in said cDNA library of claim 20, said gene comprising the DNA sequence set forth in the Sequence Listing as SEQ ID NO:15.
- 20 40. A gene expressed as a consequence of a ligand-receptor interaction and included in said cDNA library of claim 20, said gene comprising the DNA sequence set forth in the Sequence Listing as SEQ ID NO:16.
- 25 41. A gene expressed as a consequence of a ligand-receptor interaction and included in said cDNA library of claim 20, said gene comprising the DNA sequence set forth in the Sequence Listing as SEQ ID NO:17.

42. A gene expressed as a consequence of a ligand-receptor interaction and included in said cDNA library of claim 20, said gene comprising the DNA sequence set forth in the Sequence Listing as SEQ ID NO:18.
- 05
43. A gene expressed as a consequence of a ligand-receptor interaction and included in said cDNA library of claim 20, said gene comprising the DNA sequence set forth in the Sequence Listing as SEQ ID NO:19.
- 10

1/4

FIG. 1



SUBSTITUTE SHEET

FIG. 2







FIG. 5



SUBSTITUTE SHEET

## INTERNATIONAL SEARCH REPORT

International application No  
PCT/US92/10087

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : C12N 15/13, 15/12

US CL : 435/172.3, 252.3; 536/27

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.1, 172.3, 252.3, 320.1; 536/27

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, STN/MEDLINE

search terms: thiouridine, thioguanosine, cDNA, cycloheximide, subtractive

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Proceedings of the National Academy of Sciences, Vol. 81, issued February 1984, Stetler et al., "Molecular cloning of hormone-responsive genes from the yeast <i>Saccharomyces cerevisiae</i> ", pages 1144 to 1148, see entire document.	1 to 18 and 20 to 43
Y	Proceedings of the National Academy of Sciences, Vol. 83, issued July 1986, Sabath et al., "Cloned T-cell proliferation and synthesis of specific proteins are inhibited by quinine", pages 4739 to 4743, see entire document.	4, 5, 16, 23 & 24
Y	SCIENCE, Vol. 227, issued 08 March 1985, Cramer et al., "Rapid Switching of Plant Gene Expression Induced by Fungal Elicitor", pages 1240 to 1243, see the abstract.	19
Y	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol. 129, No.3, issued 28 June 1985, Foridyke, "cDNA CLONING OF mRNAs WHICH INCREASE RAPIDLY IN HUMAN LYMPHOCYTES CULTURED WITH CONCAVALIN-A AND CYCLOHEXIMIDE", pages 619 to 625, see entire document.	1 to 43



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be part of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another creation or other special reason (as specified)	*G*	document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means		
*P* document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

19 February 1993

Date of mailing of the international search report

01 MAR 1993

Name and mailing address of the ISA/  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

Authorized officer

JOHN D. ULM

Telephone No. (703) 308-0196